topotecan has been researched along with Recrudescence in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (6.49) | 18.2507 |
| 2000's | 37 (48.05) | 29.6817 |
| 2010's | 30 (38.96) | 24.3611 |
| 2020's | 5 (6.49) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, AK; Forlenza, CJ; Kernan, NA; Mauguen, A; Ramaswamy, K; Roshal, M; Shukla, N; Steinherz, PG; Sulis, ML; Trippett, T | 1 |
| Ebinger, M; Fuchs, J; Heinz, AT; Klingebiel, T; Koscielniak, E; Kratz, CP; Ljungman, G; Münter, MW; Pajtler, KW; Rößler, J; Schönstein, A; Seitz, G; Sparber-Sauer, M; Stegmaier, S; Timmermann, B; Vokuhl, C; von Kalle, T | 1 |
| Li, G; Li, J; Miao, Y; Sun, Z; Tang, B | 1 |
| Jo, DY; Ko, YB; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yun, HJ | 1 |
| Harrie, RP; Levin, AM; Owen, L | 1 |
| An, T; Bai, H; Chen, H; Duan, J; Liu, X; Lv, C; Wang, J; Wang, Y; Wang, Z; Wu, M; Yang, X; Zhao, J; Zheng, Q; Zhong, J; Zhuo, M | 1 |
| Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD | 1 |
| Imai, H; Kaburagi, T; Kaira, K; Kanazawa, K; Kasai, T; Kotake, M; Minato, K; Minemura, H; Nakamura, Y; Shibata, Y; Sugiyama, T; Yamada, Y | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Echebarria, A; Genolla, J; Llorens, V; Lopez-Almaraz, R; Minguez, P; Rodriguez, T | 1 |
| Billups, C; Davidoff, AM; Debelenko, LV; McGregor, L; Mercer, K; Morton, C; Pinto, EM; Ribeiro, RC; Rodriguez-Galindo, C; Zambetti, GP | 1 |
| Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM | 1 |
| Kobos, R; Renaud, T; Shukla, N; Steinherz, LJ; Steinherz, PG | 1 |
| Ghadimi, H; Ghassemi, F; Khodabandeh, A; Roohipoor, R; Shields, CL | 1 |
| Dang, NH; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, FB; Loyer, E; McLaughlin, P; Nastoupil, L; Oki, Y; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Westin, JR; Younes, A | 1 |
| Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
| de Groot, J; Kamiya-Matsuoka, C; Liao, B; Mella, DB; Tummala, S | 1 |
| Borders, EB; Cherry, MA; Herman, T; Holter, J; Selby, GB; Srour, SA | 1 |
| Ariyoshi, K; Nagayama, R; Okadome, M; Saito, T; Shimada, T; Shimamoto, K; Yamaguchi, S | 1 |
| Horita, N; Ikeda, M; Kaneko, T; Kobayashi, N; Kudo, M; Nagai, K; Nagakura, H; Nakashima, K; Sato, T; Shibata, Y; Shinkai, M; Tashiro, K; Tsukahara, T; Ushio, R; Watanabe, H; Yamamoto, M | 1 |
| Oskay-Ozcelik, G; Sehouli, J | 1 |
| Annibali, O; Avvisati, G; Cellini, F; Greco, R; Nobile, C; Petrucci, MT; Quattrocchi, CC; Tirindelli, MC | 1 |
| Bennett, JM; Cripe, LD; Dewald, GW; Gore, SD; Lazarus, HM; Lee, SJ; Litzow, MR; Othus, M; Paietta, EM; Rowe, JM; Tallman, MS | 1 |
| Qin, TJ; Wang, JY; Xiao, ZJ; Xu, ZF; Zhou, CL | 1 |
| Crews, KR; Inaba, H; Pounds, S; Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Stewart, CF; Yang, S | 1 |
| Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L | 1 |
| Kobos, R; Shukla, N; Steinherz, L; Steinherz, PG | 1 |
| Biernacka, B; Buczkowski, J; Krawczyk, P; Milanowski, J; Perzyło, K; Siwiec, A | 1 |
| Anderlini, P; Champlin, RE; Donato, M; Giralt, SA; Hosing, C; Kazmi, SM; Popat, U; Qazilbash, MH; Qureshi, S; Saliba, RM; Wang, M | 1 |
| Brumback, BA; Campbell, LA; Castleberry, RP; Cohn, SL; Diller, L; Frantz, CN; London, WB; Matthay, KK; Seeger, RC | 1 |
| Ashikaga, T; Bergendahl, GM; Bingham, PM; Brard, L; Ferguson, WS; Heath, BW; Higgins, TJ; Homans, AC; Kamen, BA; Lenox, SR; Saulnier Sholler, GL; Singh, AP; Slavik, MA | 1 |
| Chikamori, K; Harita, S; Hosokawa, S; Hotta, K; Kishino, D; Kiura, K; Kuyama, S; Nogami, N; Shibayama, T; Shinkai, T; Tabata, M; Takigawa, N; Tamaoki, A; Tanimoto, M; Ueoka, H | 1 |
| Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L | 1 |
| Fabbro, M; Floquet, A; Freyer, G; Gladieff, L; Hardy-Bessard, AC; Joly, F; Kaminski, MC; Kurtz, JE; Pujade-Lauraine, E; Raban, N; Ray-Coquard, I | 1 |
| Arnoulet, C; Autret, A; Blaise, D; Charbonnier, A; D'incan, E; Etienne, A; Fürst, S; Jean, E; Prébet, T; Rey, J; Vey, N | 1 |
| Barash, I; Baumgartner, R; Blank, S; Curtin, JP; Gabizon, A; Kopolovic, J; Kwa, M; Michael, J; Muggia, F; Puzanov, I; Rosengarten, O; Shavit, L | 1 |
| Adamkiewicz-Drożyńska, E; Bączek, T; Balcerska, A; Belka, M; Konieczna, L; Maciejka-Kapuścińska, L; Niedźwiecki, M; Wachowiak, J; Wiśniewski, J | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Bian, ML; Cui, Y; Guan, ZZ; Huang, CJ; Li, JD; Liu, FY; Liu, JH; Song, L; Xin, XY; Zhou, QH | 1 |
| Berger, SJ; Cooper, BW; Donaher, E; Gerson, SL; Gosky, DM; Green, SB; Hoppel, CL; Ingalls, ST; Lazarus, HM; Li, X; Rosenthal, NS | 1 |
| Ardizzoni, A; Bosquee, L; Buchholz, E; Debruyne, C; Gaafar, R; King, K; Legrand, C; Lianes, P; Manegold, C; Neumaier, C; Smit, EF; ten Velde, G | 1 |
| Corbacioglu, S; Eber, S; Gungor, T; Hummerjohann, J; Niggli, F | 1 |
| Kolb, EA; Steinherz, PG | 1 |
| Armstrong, DK | 1 |
| Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM | 1 |
| Coutinho, F; Del Giglio, A; Manhani, AR; Velasquez, WS | 1 |
| Buller, RE; Geisler, JP; Lush, R; Sanders, L; Shahin, MS; Sood, AK; Sorosky, JI; Sullivan, D | 1 |
| Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ | 1 |
| Herzog, TJ | 1 |
| Casas, F; Jeremic, B | 1 |
| Braybrooke, JP; Davies, SL; Echeta, C; Flanagan, E; Ganesan, TS; Hickson, ID; Joel, S; Levitt, NC; Madhusudan, S; Propper, DJ; Te Poele, R | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Fayad, L; Goy, A; Hagemeister, FB; Loyer, E; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Younes, A | 1 |
| Hunold, A; Jürgens, H; Liebscher, C; Paulussen, M; Ranft, A; Weddeling, N | 1 |
| Adamson, PC; Blaney, SM; Bradfield, S; Franklin, J; Hawkins, DS; Krailo, M; Reaman, G; Whitlock, JA | 1 |
| Bartlett, NL; Canellos, G; Cheson, BD; Eder, JP; Johnson, JL; Niedzwiecki, D; Smith, SM | 1 |
| Forman, E; Greenlaw, C; Kalkunte, S; McCarten, K; Saulnier Sholler, GL | 1 |
| Huber, RM; Kaubitzsch, S; Lane, S; Lilenbaum, RC; Masters, G; Treat, J; Wissel, P | 1 |
| Coutinho, F; Dantas, AA; Del Giglio, A; Manhani, AR | 1 |
| Bookman, MA | 2 |
| Fels, C; Hau, P; Janssen, G; Liebeskind, AK; Peters, O; Sauerbrey, A; Suttorp, M; Wagner, S; Wolff, JE | 1 |
| Castellano, A; De Ioris, MA; De Laurentis, C; Dominici, C; Donfrancesco, A; Garganese, MC; Ilari, I; Jenkner, A; Milano, GM | 1 |
| Carden, CP; O'Brien, ME | 1 |
| Arkenau, HT; Ethell, M; Hiwarkar, P; Morgan, G; Potter, M; Treleaven, J | 1 |
| Campana, D; Coustan-Smith, E; Gajjar, A; Hijiya, N; Pui, CH; Relling, MV; Rivera, GK; Stewart, CF; Zhou, Y | 1 |
| Baker, SD; Evans, WE; Furman, WL; Pratt, CB; Rivera, GK; Stewart, CF | 1 |
| McNeil, C | 1 |
| Alsina, M; Crowley, JJ; Kraut, EH; Laufman, LR; Salmon, SE; Taylor, SA; Wade, JL | 1 |
| Beran, M; Cortes, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Vey, N | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S | 1 |
| D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
| Chiusolo, P; Leone, G; Mazzotta, S; Mele, L; Pagano, L; Putzulu, R; Voso, MT | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X | 1 |
| Li, H; Liu, L; Zhang, W | 1 |
| Grübner, U; Höffken, K; Hoffmann, A; Kath, R; Merkel, U; Schneider, CP | 1 |
5 review(s) available for topotecan and Recrudescence
| Article | Year |
|---|---|
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients.
Topics: Anthracyclines; Antineoplastic Agents; Asian People; Humans; Japan; Lung Neoplasms; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome; White People | 2016 |
Current role and future aspects of topotecan in relapsed ovarian cancer.
Topics: Antineoplastic Agents; Female; Humans; Ovarian Neoplasms; Recurrence; Topotecan | 2009 |
Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
Topics: Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Incidence; Ovarian Neoplasms; Practice Guidelines as Topic; Receptors, Colony-Stimulating Factor; Recurrence; Risk Factors; Topotecan | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Recurrence; Salvage Therapy; Time Factors; Topotecan | 1999 |
40 trial(s) available for topotecan and Recrudescence
| Article | Year |
|---|---|
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan | 2018 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Recurrence; Temozolomide; Topotecan; Young Adult | 2014 |
Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Thiotepa; Topotecan; Vinblastine; Vinorelbine | 2014 |
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Middle Aged; Paclitaxel; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome; Young Adult | 2014 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gemtuzumab; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Topotecan | 2010 |
[Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Topotecan; Young Adult | 2009 |
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Recurrence; Retreatment; Topotecan | 2010 |
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesylates; Middle Aged; Patient Selection; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Topotecan | 2010 |
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Recurrence; Remission Induction; Topotecan; Transplantation, Autologous; Treatment Outcome | 2011 |
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Causality; Child; Child, Preschool; Confounding Factors, Epidemiologic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Models, Statistical; Neuroblastoma; Prognosis; Recurrence; Risk Factors; Topotecan; Treatment Outcome; Young Adult | 2010 |
A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Maximum Tolerated Dose; Neuroblastoma; Nifurtimox; Recurrence; Topotecan; Treatment Outcome | 2011 |
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan | 2011 |
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Recurrence; Topotecan; Uterine Cervical Neoplasms | 2012 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
[Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Recurrence; Topotecan; Treatment Outcome | 2002 |
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chemical and Drug Induced Liver Injury; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 2003 |
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Time Factors; Topotecan | 2003 |
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukemia; Male; Recurrence; Thiotepa; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine | 2004 |
Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glucocorticoids; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Recurrence; Topotecan; Treatment Outcome | 2004 |
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chromatography, High Pressure Liquid; Disease Progression; DNA; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Time Factors; Topotecan; Treatment Outcome | 2004 |
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine | 2004 |
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Middle Aged; Organophosphorus Compounds; Ovarian Neoplasms; Quality of Life; Recurrence; Topotecan | 2005 |
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Recurrence; Topotecan; Treatment Outcome | 2006 |
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Sarcoma, Ewing; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neutropenia; Recurrence; Sarcoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome | 2006 |
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
Topics: Adult; Aged; Burkitt Lymphoma; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 2006 |
Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Recurrence; Salvage Therapy; Survival Analysis; Topotecan | 2006 |
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Child; Child, Preschool; Choroid Plexus Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Glioblastoma; Hematologic Diseases; Humans; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Stomatitis; Topotecan; Treatment Outcome | 2008 |
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Dexamethasone; Female; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topotecan; Vincristine | 2008 |
Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infant; Infusions, Intravenous; Leukemia; Male; Metabolic Clearance Rate; Recurrence; Topotecan | 1996 |
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 1999 |
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Humans; Leukemia; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 2000 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Second Primary; Recurrence; Therapeutic Equivalency; Topotecan; Treatment Outcome | 2001 |
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine | 2001 |
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Disease Progression; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Ifosfamide; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Recurrence; Topotecan | 2002 |
32 other study(ies) available for topotecan and Recrudescence
| Article | Year |
|---|---|
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Clofarabine; Humans; Leukemia, Myeloid, Acute; Recurrence; Thiotepa; Topotecan; Vinorelbine; Young Adult | 2022 |
Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Chronic Disease; Cyclophosphamide; Etoposide; Humans; Polyketides; Recurrence; Retrospective Studies; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Topotecan | 2023 |
Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
Topics: Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Recurrence; STAT5 Transcription Factor; Topotecan | 2023 |
Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Palliative Care; Recurrence; Retrospective Studies; Topotecan; Treatment Outcome | 2020 |
Recurrent Subconjunctival Hemorrhage in a Child With an Orbital Mass.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Eye Hemorrhage; Female; Humans; Infant; Neuroblastoma; Orbital Neoplasms; Recurrence; Topotecan; Treatment Outcome; Ultrasonography | 2021 |
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Topics: Aged; Biomarkers, Tumor; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Recurrence; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Topotecan | 2018 |
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Recurrence; Retreatment; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2018 |
Dosimetry-based high-activity therapy with
Topics: 3-Iodobenzylguanidine; Adolescent; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Progression-Free Survival; Radiometry; Recurrence; Remission Induction; Retrospective Studies; Risk; Topotecan; Treatment Outcome; Young Adult | 2019 |
Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Child; Disease Models, Animal; Female; Gene Expression Profiling; Humans; Male; Mice; Recurrence; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Female; Humans; Infant; Intravitreal Injections; Male; Melphalan; Neoplasm Seeding; Recurrence; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan; Vitreous Body | 2014 |
Recurrent encephaloclastic cyst induced by intraventricular topotecan.
Topics: Aged; Brain; Cysts; Drug Delivery Systems; Female; Humans; Injections, Intraventricular; Magnetic Resonance Imaging; Meningeal Neoplasms; Recurrence; Topotecan | 2015 |
Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retreatment; Thiotepa; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
[Nogitecan Hydrochloride Treatment for Patients with Recurrent Ovarian Cancer].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Recurrence; Tomography, X-Ray Computed; Topoisomerase Inhibitors; Topotecan; Treatment Outcome | 2015 |
The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Dexamethasone; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Recurrence; Temozolomide; Topotecan | 2009 |
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Topotecan; Vinblastine; Vinorelbine | 2010 |
[Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Poland; Proportional Hazards Models; Recurrence; Survival Analysis; Topotecan; Treatment Outcome | 2010 |
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Topotecan | 2012 |
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Creatinine; Deoxycytidine; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Quality of Life; Recurrence; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Taxoids; Thrombosis; Topotecan | 2012 |
Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calibration; Chromatography, Liquid; Chromatography, Reverse-Phase; Cladribine; Drug Dosage Calculations; Drug Monitoring; Female; Half-Life; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Linear Models; Metabolic Clearance Rate; Recurrence; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topotecan | 2012 |
Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Burkitt Lymphoma; Child; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Humans; Immunotherapy; Leukemic Infiltration; Male; Meninges; Methotrexate; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Testis; Topotecan; Transplantation, Autologous; Vindesine | 2003 |
In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Recurrence; Topotecan | 2004 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Antitumor activity of nifurtimox observed in a patient with neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chagas Disease; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Neuroblastoma; Nifurtimox; Recurrence; Remission Induction; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2006 |
Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Female; Gefitinib; Humans; Neuroblastoma; Quinazolines; Radionuclide Imaging; Recurrence; Topotecan; Treatment Outcome | 2007 |
Small-cell lung cancer, getting smaller but still difficult to treat.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Humans; Lung Neoplasms; Radiotherapy, Adjuvant; Recurrence; Topotecan | 2008 |
The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Topotecan; Vinblastine; Vinorelbine | 2008 |
Topotecan: after FDA and ASCO, what's next?
Topics: Antineoplastic Agents; Camptothecin; Female; Genital Neoplasms, Female; Humans; Recurrence; Topotecan; United States; United States Food and Drug Administration | 1996 |
Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Topotecan | 1998 |
[Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients].
Topics: Adult; Antineoplastic Agents; Female; Humans; Middle Aged; Ovarian Neoplasms; Recurrence; Topotecan; Treatment Outcome | 2001 |
Recurrent ovarian cancer as chronic disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chronic Disease; Deoxycytidine; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Recurrence; Topotecan; Trastuzumab | 2002 |